🚀 VC round data is live in beta, check it out!
Virbac Valuation Multiples
Discover revenue and EBITDA valuation multiples for Virbac and similar public comparables like Santen Pharmaceutical, Brightgene Bio-medical, Structure Therapeutics, Kanghong Pharmaceutical and more.
Virbac Overview
About Virbac
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
Founded
1968
HQ
Employees
6.4K
Website
Financials (LTM)
EV
$4B
Virbac Financials
Virbac reported last 12-month revenue of $2B and EBITDA of $344M.
In the same LTM period, Virbac generated $344M in EBITDA and $186M in net income.
Revenue (LTM)
Virbac P&L
In the most recent fiscal year, Virbac reported revenue of $2B and EBITDA of $326M.
Virbac expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | — | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $344M | XXX | $326M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $186M | XXX | $171M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $141M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Virbac Stock Performance
Virbac has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Virbac's stock price is $426.53.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 0.2% | XXX | XXX | XXX | $20.43 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVirbac Valuation Multiples
Virbac trades at 2.2x EV/Revenue multiple, and 11.0x EV/EBITDA.
EV / Revenue (LTM)
Virbac Financial Valuation Multiples
As of April 18, 2026, Virbac has market cap of $4B and EV of $4B.
Equity research analysts estimate Virbac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Virbac has a P/E ratio of 19.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | 11.6x | XXX | XXX | XXX |
| EV/EBIT | 13.6x | XXX | 14.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.4x | XXX | XXX | XXX |
| P/E | 19.2x | XXX | 20.9x | XXX | XXX | XXX |
| EV/FCF | 36.0x | XXX | 25.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Virbac Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Virbac Margins & Growth Rates
Virbac's revenue in the last 12 month grew by 8%.
Virbac's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Virbac's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Virbac's rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Virbac Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Virbac Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Pet Care comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Virbac | XXX | XXX | XXX | XXX | XXX | XXX |
| Santen Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Brightgene Bio-medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Structure Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kanghong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Kangmei Pharmaceutical Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Virbac M&A Activity
Virbac acquired XXX companies to date.
Last acquisition by Virbac was on XXXXXXXX, XXXXX. Virbac acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Virbac
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVirbac Investment Activity
Virbac invested in XXX companies to date.
Virbac made its latest investment on XXXXXXXX, XXXXX. Virbac invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Virbac
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Virbac
| When was Virbac founded? | Virbac was founded in 1968. |
| Where is Virbac headquartered? | Virbac is headquartered in France. |
| How many employees does Virbac have? | As of today, Virbac has over 6K employees. |
| Is Virbac publicly listed? | Yes, Virbac is a public company listed on Euronext Paris. |
| What is the stock symbol of Virbac? | Virbac trades under VIRP ticker. |
| When did Virbac go public? | Virbac went public in 1989. |
| Who are competitors of Virbac? | Virbac main competitors are Santen Pharmaceutical, Brightgene Bio-medical, Structure Therapeutics, Kanghong Pharmaceutical. |
| What is the current market cap of Virbac? | Virbac's current market cap is $4B. |
| What is the current revenue of Virbac? | Virbac's last 12 months revenue is $2B. |
| What is the current revenue growth of Virbac? | Virbac revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Virbac? | Current revenue multiple of Virbac is 2.2x. |
| Is Virbac profitable? | Yes, Virbac is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Virbac? | Virbac's last 12 months EBITDA is $344M. |
| What is Virbac's EBITDA margin? | Virbac's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Virbac? | Current EBITDA multiple of Virbac is 11.0x. |
| What is the current FCF of Virbac? | Virbac's last 12 months FCF is $105M. |
| What is Virbac's FCF margin? | Virbac's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Virbac? | Current FCF multiple of Virbac is 36.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.